Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease.
Rallybio has raised $6.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2024.
Rallybio's investors include Connecticut Innovations, Canaan Partners, Pivotal bioVenture Partners, The Rise Fund, 5AM Ventures.
Rallybio is headquartered in Farmington, United States.
Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease.
Rallybio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rallybio — Funding & Investors." VCBacked, April 10, 2024, https://www.vcbacked.co/company/rallybio. Accessed September 28, 2026.
VCBacked. (2024). Rallybio — Funding & Investors. Retrieved September 28, 2026, from https://www.vcbacked.co/company/rallybio
{{cite web |title=Rallybio — Funding & Investors |url=https://www.vcbacked.co/company/rallybio |website=VCBacked |access-date=September 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated